Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jordan Margo

Ophthalmology Morganton, NC Medical Doctor

NPI 1225390834 CMS profile 2788144

335 E Parker Rd, Morganton, NC 28655

Open in the dashboard

General payments

$1,327

47 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,150 paid to institutions, not to them · program year 2025

Through program year 2025, Jordan Margo of Morganton, NC is reported in the CMS Open Payments database as having received $1,327 across 47 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,150 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 50th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $683 16
2024 General $118 4
2023 General $242 10
2022 General $78 4
2021 General $17 1
2020 General $29 2
2019 General $161 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordan Margo
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Jordan Margo were reported at $683. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Jordan Margo Ophthalmology median Middle half National median
2019 $161 $258 $104–$655 $163
2020 $29 $126 $45–$321 $114
2021 $17 $205 $76–$534 $132
2022 $78 $266 $100–$678 $149
2023 $242 $308 $117–$745 $160
2024 $118 $340 $127–$846 $164
2025 $683 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $394 19 payments
  2. New World Medical,Inc. $345 3 payments
  3. TissueTech, Inc. $114 4 payments
  4. Bausch & Lomb Americas Inc. $86 4 payments
  5. NotalVision $77 2 payments
  6. CooperVision Inc. $69 1 payment
  7. Bausch & Lomb, a division of Bausch Health US, LLC $65 4 payments
  8. Tarsus Pharmaceuticals, Inc. $21 1 payment
  9. Rayner Intraocular Lenses Limited $20 1 payment
  10. Dompe US, Inc. $19 1 payment
  11. Other $117 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,309 46 payments
  2. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. Kahook Dual Blade $345 3 payments
  2. Clearpath $345 3 payments
  3. Ahmed Glaucoma Valve $345 3 payments
  4. Streamline $345 3 payments
  5. Via360 $345 3 payments
  6. HYDRUS Microstent $339 16 payments
  7. Foresee Home $77 2 payments
  8. MyDay Contact Lens $69 1 payment
  9. MIEBO $58 3 payments
  10. LOTEMAX SM $46 3 payments
  11. Other $476 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,601

Median for Ophthalmology: 891

Drug cost

$246,770

Median for Ophthalmology: $68,233

Branded share of claims

41.5%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 153 $172,140
Prednisolone Acetate Generic 411 $20,529
Xiidra Lifitegrast Brand 11 $15,248
Lumigan Bimatoprost Brand 17 $8,224
Cyclosporine Generic 13 $6,691
Combigan Brimonidine Tartrate/Timolol Brand 14 $6,462
Moxifloxacin Moxifloxacin Hcl Brand 85 $3,689
Latanoprost Generic 232 $2,539
Fluorometholone Generic 24 $2,401
Diclofenac Sodium Generic 155 $1,712

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$249,771

Medicare's payments for the services billed

Medicare patients

798

Average age 76

Services billed

2,285

517 women, 281 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 47%
Diabetes 31%
Ischemic heart disease 21%
Chronic kidney disease 21%
Depression 20%
Atrial fibrillation 16%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record